"Reaxys' new content and capability expansion of the user interface expands horizons for researchers across all chemistry related domains. Reaxys, in combination with Reaxys Medicinal Chemistry, the domain specific solution, enables users to make more confident decisions about compound selection and synthesis much earlier in the process, improving the likelihood of developing a successful drug and reducing the costs associated with a drug candidate failure in the pre-clinical or clinical development stages," said Meeuwis van Arkel, Vice President Product Development at Elsevier. "Reaxys is interoperable with other innovative solutions which assist researchers across disciplines; this interoperability is vital in promoting organizational efficiency and R&D efficacy."
Reaxys is a key pillar of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow. Reaxys works with solutions including; ScienceDirect, for immediate full-text access; Scopus, for in-depth bibliometric information; PharmaPendium for a comprehensive view into FDA/EMA approved drugs.
To view Reaxys' new interface and for more information go to: http://www.elsevier.com/reaxys
About Reaxys®Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys. Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license. About Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). Media contact Liz Griffioen Elsevier +31-20-485-2247 firstname.lastname@example.org SOURCE Elsevier
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV